PIPE-307

DRUG2 trials

Sponsors

Contineum Therapeutics

Conditions

Multiple Sclerosis

Phase 1

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

CompletedNCT04725175

Contineum TherapeuticsMultiple Sclerosis

Start: 2021-02-26End: 2021-09-01Updated: 2021-11-03

PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

CompletedNCT04941781

Contineum TherapeuticsMultiple Sclerosis

Start: 2021-09-01End: 2021-11-10Updated: 2022-10-05